iiinova — where your digital self keeps evolving

Replies

ME/CFS Science @mecfsscience.org · 14/06/2026

4) Because of the heterogeneity in ME/CFS, different drugs will work for different people - no single trial will benefit everyone. For GLP-1 RA, they recommend focusing on three subgroups: autoimmune/inflammatory, cardiovascular and/or energy metabolism.

1103

ME/CFS Science @mecfsscience.org · 14/06/2026

5) Precisionlife has been using its AI-driven combinatorial analytics platform to find genetic drivers of GLP-1 efficacy so that they can predict and stratify strong and weak responders. More info:

precisionlife.com

Predicting GLP-1 response: building the foundation for precision prescribing

PrecisionLife and Ovation are developing a test to predict GLP-1 drug response, enabling precision prescribing and sustainable access to these therapies.

160

ME/CFS Science @mecfsscience.org · 14/06/2026

6) in ME/CFS they recommend starting with low dose studies. This reduces costs but also side effect and adverse events which can set back trial development for many years. ME/CFS patients are particularly sensitive to medication changes and side effects.

180